1. Bruno JJ, Ellis JJ. Herbal use among US elderly: 2002 National Health Inter- view Survey. Ann Pharmacother 2005; 39: 643–648.
2. Slone Epidemiology Center. Patterns of Medication Use in the United States 2006. A Report from the Slone Survey. Slone Epidemiology Center at Boston University: Boston, Mass., 2006.
3. CDC. Incidence of Diagnosed Diabetes Per 1000 Population Aged 18–79 Years, by Sex and Age, United States, 1997–2005. Centers for Disease Control and Pre- vention (CDC): Atlanta, Georgia, 2007; Available at: 
4. Marshall S, Bacote V, Traxinger R. Dis- covery of a metabolic pathway mediat- ing glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induc- tion of insulin resistance. J Biol Chem 1991; 266: 4706–4712.
5. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab 2008; 295: E17–E28.
6. Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci 2007; 333: 333–339.
7. Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 2007; 66: 260–262.
8. Dahmer S, Schiller RM. Glucosamine. Am Fam Physician 2008; 78: 471–476.
9. Shankar RR, Zhu J-S, Baron AD. Glucosamine infusion in rats mim- ics the beta-cell dysfunction of non- insulin-dependent diabetes mellitus. Metabolism 1998; 47: 573–577.
10. Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 2006; 55: 3142–3150.
11. Quastel JH. Intestinal absorption of sugars and amino acids. Am J Clin Nutr 1960; 8: 137–146.
12. Hastings TH, Landau BR. Specificity of sugar transport by the intestine of the hamster. Am J Physiol 1960; 198: 99–102.
13. Neale RJ, Wiseman G. The use of dietary-restricted rat intestine for active transport studies. J Physiol 1969; 205: 159–178.
14. Faust RG, Leadbetter MG, Plenge RK, McCaslin AJ. Active sugar transport by the small intestine. The effects of sugars, 
15. Hirayama BA, Loo DD, D ́ ı ez-Sampedro A, et al. Sodium-dependent reorganiza- tion of the sugar-binding site of SGLT1. Biochemistry 2007; 46: 13391–1406.
16. Roda A, Sabatini L, Barbieri A, et al. Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. J Chromatogr B 2006; 844: 119–126.
17. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capa- bility for peripheral effectiveness. Ann Rheum Dis 2006; 65: 222–226.
18. Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007; 15: 764–772.
19. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13: 1041–1049.
20. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excre- tion of glucosamine sulfate. A review. Arzneimittelforschung 2001; 51: 699–725.
21. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molec- ular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002; 23: 217–225.
22. Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm Drug Dispos 2004; 25: 109–116.
23. Laverty S, Sandy JD, Celeste C, Vachon P, Marier J-F, Plaas AH. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 2005; 52: 181–191.
24. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 2002; 5: 181–184.
25. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in 
26. Aghazadeh-Habashi A, Ibrahim A, Car- ran J, Anastassiades T, Jamali F. Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. J Pharm Pharm Sci 2006; 9: 359–364.
27. Crociani F, Alessandrini A, Mucci MM, Biavati B. Degradation of complex car- bohydrates by Bifidobacterium spp. Int J Food Microbiol 1994; 24: 199–210.
28. Salyers AA, Vercellotti JR, West SEH, Wilkins TD. Fermentation of mucin and plant polysaccharides by strains of bac- teroides from the human colon. Appl Environ Microbiol 1977; 33: 319–322.
29. Kajinuma H, Kuzuya T, Ide T, Tyler JM. Effects of glucosamine on insulin and glucagon secretion in dogs and ducks. Endocrinol Jpn 1975; 22: 517–523.
30. Giaccari A, Morviducci L, Zorretta D, et al. In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: possible relevance to the maladaptive responses to chronic hyperglycaemia. Diabetologia 1995; 38: 518–524.
31. Baron AD, Zhu J-S, Zhu J-H, Weldon H, Maianu L, Garvey WT. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle: implications for glucose toxicity. J Clin Invest 1995; 96: 2792–2801.
32. Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion induces insulin resistance in nor- moglycemic but not in hyperglycemic conscious rats. J Clin Invest 1995; 96: 132–140.
33. Hawkins M, Angelov I, Liu R, Barzilai N, Rossetti L. The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem 1997; 272: 4889–4895.
34. Virkamäki A, Daniels MC, Hämaläinen S, Utriainen T, McClain D, Yki-Järvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues. Endocrinology 1997; 138: 2501–2507.
35. Holmäng A, Nilsson C, Niklasson M, Larsson BM, Lonroth P. Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin. Diabetes 1999; 48: 106–111.
36. Kim YB, Zhu JS, Zierath JR, Shen HQ, Baron AD, Kahn BB. Glucosamine infusion in rats rapidly impairs insulin stim- ulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle. Diabetes 1999; 48: 310–320.
37. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, Yki-Jarvinen H. Activation of the hexosamine pathway by 
38. Spampinato D, Giaccari A, Trischitta V, et al. Rats that are made insulin resis- tant by glucosamine treatment have impaired skeletal muscle insulin recep- tor phosphorylation. Metabolism 2003; 52: 1092–1095.
39. Robertson MW, Dunshea FR, Goddard ME, Leury BJ. Stimulation of the hexosamine biosynthetic pathway by glucosamine in sheep. Asia Pac J Clin Nutr 2005; 14: (suppl): S79.
40. Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 2000; 49: 926–935.
41. Pouwels M-J, Jacobs JR, Span PN, Lut- terman JA, Smits P, Tack CJ. Short- term glucosamine infusion does not affect insulin sensitivity in humans. J Clin Endocrinol Metab 2001; 86: 2099–2103.
42. Oguchi M, Miyatake Y, Ayabe J, Akamatsu N. Phosphorylation of D-glucosamine by rat liver glucokinase. J Biochem 1975; 77: 1117–1121.
43. Agius L, Stubbs M. Investigation of the mechanism by which glucose analogues cause translocation of glucokinase in hepatocytes: evidence for two glucose binding sites. Biochem J 2000; 346: 413–421.
44. Albert SG, Oiknine RF, Parseghian S, Mooradian AD, Haas MJ, McPherson T. The effect of glucosamine on serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007; 30: 2800–2803.
45. Yu JG, Boies SM, Olefsky JM. The effect of oral glucosamine sulfate on insulin sensitivity in human subjects. Diabetes Care 2003; 26: 1941–1942.
46. Scroggie DA, Albright A, Harris MD. The effect of glucosamine- chondroitin supplementation on glyco- sylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo- controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163: 1587–1590.
47. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982; 3: 157–168.
48. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795–808.
49. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12: 506–511.
50. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 2002; 41: 279–284.
51. Pavelká K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3- year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–2123.
52. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251–256.
53. Almada AL, Harvey P, Platt K. Effect of chronic oral glucosamine sulfate upon fasting insulin resistance index (FIRI) in non-diabetic individuals. FASEB J 2000; 14: A750 [Abstract 521.15].
54. Giordano N, Nardi P, Senesi M, et al. Efficacia e tollerabilità della glu- cosamina solfato nel trattamento della gonartrosi. [The efficacy and safety of glucosamine sulfate in the treatment of gonarthritis]. Clin Ter 1996; 147: 99–105.
55. Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 51–59.
56. D’Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2: 504–508.
57. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo- controlled double-blind investigation. Clin Ther 1980; 3: 260–272.
58. Crolle G, D’Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104–109.
59. Laferrère B, Garcia-Lorda P, Russell CD, Pi-Sunyer FX. Effect of oral glucosamine sulfate on serum leptin levels in human subjects. Nutrition 2004; 20: 321–322.
60. Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7: 110–114.
61. Rovati LC. Clinical research in osteoarthritis: design and results of 
62. Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibupro- fen in patients with knee osteoarthritis. Arzneimittelforschung 1998; 48: 469–474.
63. Valensi P, Schwarz EH, Hall M, Fel- ton AM, Maldonato A, Mathieu C. Pre- diabetes essential action: a European perspective. Diabetes Metab 2005; 31: 606–620.
64. IDF. Prevalence estimates of diabetes mellitus (DM), 2010. In Diabetes Atlas: The e-Atlas. (4th edn), The International Diabetes Federation (IDF): Brussels, Belgium, 2010; Available at: 
65. EC. Population Statistics: Detailed Tables. Office for Official Publications of the European Communities: Lux- embourg, 2004; Available at: http:// epp.eurostat.ec.europa.eu/cache/ITY OFFPUB/KS-BP-04-001/EN/KS-BP-04- 001-EN.PDF. [23 November 2009].
66. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30: 357–363.
67. Marshall S, Nadeau O, Yamasaki K. Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes: differential effects on glucosamine 6-phosphate, UDP- N-acetylglucosamine, and ATP levels. J Biol Chem 2004; 279: 35313–35319.
68. Heart E, Choi WS, Sung CK. Glucosamine-induced insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2000; 278: E103–E112.
69. Echard BW, Talpur NA, Funk KA, Bagchi D, Preuss HG. Effects of oral glucosamine and chondroitin sulfate alone and in combination on the metabolism of SHR and SD rats. Mol Cell Biochem 2001; 225: 85–91.
70. McNamara PS, Barr SC, Erb HN. Hema- tologic, hemostatic, and biochemical effects in dogs receiving an oral chon- droprotective agent for thirty days. Am J Vet Res 1996; 57: 1390–1394.
71. Stender S, Astrup P. Glucosamine and experimental atherosclerosis. Increased wet weight and charged composition of cholesterol fatty acids in aorta of rabbits fed a cholesterol-enriched diet with added glucosamine. Atherosclerosis 1977; 26: 205–213.